Boys, number (%) | 144 (69.9%) |
Age, mean (SD) | 10.4 years (3.7) |
BMI, mean (SD) | 17.2 (3.1) |
Asthma maintenance therapy, n (%) | 195 (94.7) |
ICS ≤250 μg/day* | 143 (73.3%) |
ICS 251–500 μg/day | 44 (22.5%) |
ICS >500 μg/day | 1 (<1%) |
Combination therapy (ICS+LABA) | 51 (26.1%) |
Allergic rhinitis therapy, n (%) | 105 (51%) |
Nasal corticosteroids | 43 (40.9%) |
Oral antihistamines | 19 (18.1%) |
Montelukast | 4 (3.8%) |
Combination | 31 (29.5%) |
FVC, mean (SD) | 101.3% pred (12.0) |
FEV1, mean (SD) | 100.3% pred (14.7) |
FeNO, median (IQR) | 12.5 ppb (0–24) |
IgE, median (IQR) | 247 kU/litre (55–702) |
↵* Daily dose of fluticasone (or equivalent).
BMI, body mass index (body weight (in kg) divided by height (in cm) squared); ICS, inhaled corticosteroids; LABA, long-acting β agonist; FeNO, fraction of nitric oxide in exhaled air; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; pred, predicted.